Month: May 2021
Excerpt from the Press Release: NEWTOWN, Pa., May 21, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first patient has been dosed in the U.S. Phase 1 clinical trial of ON 123300, the Company’s proprietary, novel…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass. and WESTMINSTER, Colo., May 12, 2021 /PRNewswire/ — Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, andFlagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that they have developed an image analysis RNAscope® assay that is being used successfully for prospective patient enrollment in a clinical trial.…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the completion of enrollment in its Phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD and requiring continued anti-vascular…
Read More
Excerpt from the Article: Researchers at University of California San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays. “It’s a pilot study to evaluate whether ultrasound stimulation focused on the spleen can…
Read More
Excerpt from the Press Release: SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced encouraging interim Phase 1 data from the Company’s off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute myeloid leukemia (AML). The ongoing…
Read More
Excerpt from the Press Release: Computer program can accurately predict 80 percent of cases where COVID-19 patients will develop life-threatening conditions within four days. Chest X-rays aren’t just for diagnosing COVID-19. Newly published research now shows that these images can be part of a system that accurately predicts which patients will develop life-threatening conditions within…
Read More
Excerpt from the Press Release: SAN CARLOS, Calif., May 12, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced that the Journal of Clinical Oncology has published a manuscript of clinical data for Cohort 2 in the C-144-01…
Read More
Excerpt from the Press Release: WALNUT CREEK, CA and LONDON, UK / ACCESSWIRE / May 3, 2021 / Vivacitas Oncology, Inc. (“Vivacitas” or the “Company“), a clinical stage biopharmaceutical company focused on tough to treat cancers, and Image Analysis Group (“IAG”), a leading global medical imaging company, are collaborating to apply Artificial Intelligence (AI) technology and…
Read More
Excerpt from the Press Release: SAN MATEO, Calif., May 4, 2021 /PRNewswire/ — Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the completion of enrollment of the first cohort of patients being treated with VT3989 in its Phase 1 clinical study. The Company anticipates enrolling the next…
Read More
Excerpt from the Article: In February, the European Medicines Agency (EMA) released the fourth version of its Guidance on the Management of Clinical Trials During the COVID-19 (Coronavirus) Pandemic. As the pandemic continues to impact clinical research worldwide, these updated guidelines reflect the EMA’s evolving stance, clarifying questions raised by previous versions and taking into account…
Read More- « Previous
- 1
- 2
- 3
- 4
- Next »